Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) Overview | 7 | 1 |
| Therapeutics Development | 8 | 4 |
| Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) Products under Development by Stage of Development | 8 | 1 |
| Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) Products under Development by Therapy Area | 9 | 1 |
| Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) Products under Development by Indication | 10 | 2 |
| Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) Products under Development by Companies | 14 | 2 |
| Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) Products under Development by Universities/Institutes | 16 | 2 |
| Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) Therapeutics Assessment | 18 | 6 |
| Assessment by Monotherapy/Combination Products | 18 | 1 |
| Assessment by Mechanism of Action | 19 | 1 |
| Assessment by Route of Administration | 20 | 2 |
| Assessment by Molecule Type | 22 | 2 |
| Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) Companies Involved in Therapeutics Development | 24 | 8 |
| Array BioPharma Inc. | 24 | 1 |
| Bristol-Myers Squibb Company | 25 | 1 |
| Genentech, Inc. | 26 | 1 |
| Nimbus Therapeutics, LLC | 27 | 1 |
| Portola Pharmaceuticals, Inc. | 28 | 1 |
| Sareum Holdings Plc | 29 | 1 |
| Takeda Pharmaceutical Company Limited | 30 | 1 |
| Theravance Biopharma, Inc. | 31 | 1 |
| Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) Drug Profiles | 32 | 15 |
| ARRY-111 Drug Profile | 32 | 1 |
| cerdulatinib Drug Profile | 33 | 3 |
| SAR-20347 Drug Profile | 36 | 2 |
| SART-1 Drug Profile | 38 | 1 |
| SART-29 Drug Profile | 39 | 1 |
| SART-33 Drug Profile | 40 | 1 |
| Small Molecule to Inhibit TYK2 for Immunology Drug Profile | 41 | 1 |
| Small Molecule to Inhibit TYK2 for Psoriasis and IBD Drug Profile | 42 | 1 |
| Small Molecules to Inhibit TYK2 Drug Profile | 43 | 1 |
| Small Molecules to Inhibit Tyk2 for Inflammation and Oncology Drug Profile | 44 | 1 |
| Synthetic Peptides to Inhibit Tyrosine Kinase 2 for Inflammatory Diseases Drug Profile | 45 | 1 |
| TD-1473 Drug Profile | 46 | 1 |
| Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) Discontinued Products | 47 | 1 |
| Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) Featured News &Press Releases | 48 | 13 |
| Jun 09, 2016: Theravance Biopharma Reports Positive Results From Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor | 48 | 1 |
| Jun 01, 2016: Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings | 49 | 1 |
| Apr 14, 2016: Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation at American Association for Cancer Research (AACR) Annual Meeting 2016 | 50 | 1 |
| Mar 18, 2016: Theravance Biopharma Presents Positive Results From a Preclinical Colitis Model for TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor | 50 | 1 |
| Dec 10, 2015: Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase Inhibitor | 51 | 1 |
| Dec 10, 2015: Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase Inhibitor | 52 | 1 |
| Dec 05, 2015: Portola Pharmaceuticals Announces Cerdulatinib Data Presentation at the 2015 American Society of Hematology Annual Meeting and Exposition | 53 | 1 |
| Nov 10, 2015: Nimbus Therapeutics Announces Progress on Key Therapeutic Programs | 54 | 1 |
| Nov 02, 2015: Theravance Biopharma Submits Investigational New Drug Application for TD-1473, a GI-Targeted Pan-Janus Kinase Inhibitor | 55 | 1 |
| Jun 17, 2015: Sareum Notified Of Funding Award From Innovate UK | 55 | 1 |
| May 29, 2015: Portola Pharmaceuticals Presents Updated Data From Ongoing Phase 1/2a Study of Dual Kinase Inhibitor Cerdulatinib | 56 | 1 |
| May 18, 2015: Portola Pharmaceuticals Announces Upcoming Data Presentation on Dual Kinase Inhibitor Cerdulatinib at American Society of Clinical Oncology Annual Meeting | 57 | 1 |
| Nov 10, 2014: Sareum Holdings First Patent Grant for Sareum's TYK2 Kinase Inhibitor Programme | 58 | 1 |
| Nov 06, 2014: Portola Pharmaceuticals Announces Upcoming Presentations on Cerdulatinib at the American Society of Hematology 2014 Annual Meeting | 59 | 1 |
| Oct 01, 2014: Sareum Holdings Promising Step in Psoriasis Drug Development | 59 | 2 |
| Appendix | 61 | 2 |
| Methodology | 61 | 1 |
| Coverage | 61 | 1 |
| Secondary Research | 61 | 1 |
| Primary Research | 61 | 1 |
| Expert Panel Validation | 61 | 1 |
| Contact Us | 61 | 1 |
| Disclaimer | 62 | 1 |